Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
RASH
MCID: EXN002
MIFTS: 58

Exanthem (RASH)

Categories: Infectious diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Exanthem

About this section

MalaCards integrated aliases for Exanthem:

Name: Exanthem 12 6 15 17
Exanthema 12 44
Rash 12 15
Rashes 42

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:0050486
ICD9CM 34 782.1
MeSH 44 D005076
NCIt 50 C111884
SNOMED-CT 67 112625008
ICD10 32 R21
UMLS 71 C0015230
Sources

Summaries for Exanthem

About this section
MedlinePlus : 42 A rash is an area of irritated or swollen skin. Many rashes are itchy, red, painful, and irritated. Some rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get rashes. Contact dermatitis is a common type of rash. It causes redness, itching, and sometimes small bumps. You get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. Some rashes develop right away. Others form over several days. Although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. Because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary : Exanthem, also known as exanthema, is related to viral exanthem and severe cutaneous adverse reaction. An important gene associated with Exanthem is SYK (Spleen Associated Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Nevirapine and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and myeloid, and related phenotypes are Decreased cell viability after pRB stimulation and homeostasis/metabolism

Disease Ontology : 12 A skin disease that is characterized by a rash that results from a variety of causes including bacteria, viruses, toxins, drugs and autoimmune disorders.

Wikipedia : 74 An exanthem is a widespread rash occurring on the outside of the body and usually occurring in children.... more...

Sources

Related Diseases for Exanthem

About this section

Diseases in the Exanthem family:

Bacterial Exanthem Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1013)
# Related Disease Score Top Affiliating Genes
1 viral exanthem 32.7 TNF CRP CD8A CD4
2 severe cutaneous adverse reaction 32.0 TNF GPT CYP3A4 CTLA4 CRP CD8A
3 measles 31.0 TNF IL6 IL2 IFNA1
4 drug reaction with eosinophilia and systemic symptoms 31.0 TNF CRP
5 meningitis 30.9 TNF IL6 IL2 CRP ALB
6 pustulosis of palm and sole 30.9 TNF CRP CCR6
7 vasculitis 30.8 TNF IL6 CTLA4 CRP
8 purpura 30.8 TNF IL6 CRP
9 allergic disease 30.8 TNF SYK IL6 IL2 ICOSLG CTLA4
10 drug allergy 30.8 GPT CYP3A4 CRP CD4 ALB
11 scarlet fever 30.8 TNF CRP ALB
12 pfeiffer syndrome 30.7 IL2 HRAS H2AC18 CD8A CD4 CCR6
13 conjunctivitis 30.7 TNF IL6 IL2
14 contact dermatitis 30.7 TNF IL6 IL2 CD4 CCR6
15 erythema multiforme 30.7 TNF IL6 IL2
16 chickenpox 30.7 TNF IL6 IL2 IFNA1 ICOSLG CTLA4
17 mouth disease 30.7 IL6 IFNA1 H2AC18 CRP CCR6
18 erythema nodosum 30.6 TNF IL6 CTLA4 CRP
19 african tick-bite fever 30.6 TNF IL6 GPT
20 pharyngitis 30.6 TNF IL6 GPT CRP CD8A CD4
21 severe acute respiratory syndrome 30.6 TNF IL6 IFNA1 CRP
22 erysipelas 30.6 TNF IL6 IL2 CRP
23 allergic contact dermatitis 30.5 TNF IL6 CD4 CCR6
24 psoriasis 30.5 TNF IL6 IL2 CTLA4 CD4 CCR6
25 toxic shock syndrome 30.5 TNF IL6 IL2 EGFR CRP
26 lymphadenitis 30.5 TNF ICOSLG CRP CD8A CD4 CCR6
27 uveitis 30.5 TNF IL6 IL2 CTLA4
28 dermatitis 30.5 TNF IL6 IL2 CTLA4 CD8A CD4
29 secondary syphilis 30.4 CRP CD8A CD4
30 stomatitis 30.4 TNF IL6 IL2 IFNA1 CD4
31 herpes zoster 30.4 TNF IL2 IFNA1 ICOSLG CD8A CD4
32 pneumonia 30.4 TNF IL6 IFNA1 GPT CRP CD8A
33 chlamydia 30.4 TNF IL6 CRP
34 rubella 30.4 TNF IL6 IL2
35 thrombocytopenic purpura, autoimmune 30.4 ICOSLG CD4 CCR6
36 enterocolitis 30.4 TNF IL6 CRP
37 monkeypox 30.4 IFNA1 CD8A CD4
38 parotitis 30.4 CRP CD8A CD4 ALB
39 meningoencephalitis 30.4 TNF IL6 CRP CD8A CD4 CCR6
40 myelitis 30.4 TNF IL6 ICOSLG CCR6
41 panniculitis 30.3 TNF CRP CD8A CD4
42 adult-onset still's disease 30.3 TNF IL6 CRP
43 rosacea 30.3 TNF IL6 CRP CCR6
44 igg4-related disease 30.3 ICOSLG CRP CCR6
45 granulomatous dermatitis 30.3 TNF CD8A CD4
46 interstitial nephritis 30.3 ICOSLG CRP ALB
47 disseminated intravascular coagulation 30.3 TNF IL6 GPT CRP
48 histoplasmosis 30.3 TNF CD4 CCR6
49 streptococcal toxic-shock syndrome 30.3 TNF IL6 IL2
50 poliomyelitis 30.3 TNF IFNA1 CD8A CD4

Graphical network of the top 20 diseases related to Exanthem:



Diseases related to Exanthem
Sources

Symptoms & Phenotypes for Exanthem

About this section

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell viability after pRB stimulation GR00230-A-1 8.32 SYK

MGI Mouse Phenotypes related to Exanthem:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 ALB CCR6 CD274 CD4 CRP CTLA4
2 endocrine/exocrine gland MP:0005379 10.26 ALB CD4 CD8A CTLA4 EGFR ERBB2
3 cardiovascular system MP:0005385 10.25 ALB CRP CTLA4 EGFR ERBB2 HRAS
4 immune system MP:0005387 10.25 ALB CCR6 CD274 CD4 CD8A CRP
5 digestive/alimentary MP:0005381 10.19 ALB CD4 CTLA4 EGFR ERBB2 HRAS
6 integument MP:0010771 10.1 CD274 CD4 CD8A CTLA4 EGFR ERBB2
7 liver/biliary system MP:0005370 9.97 ALB CTLA4 EGFR IL2 IL6 KIT
8 neoplasm MP:0002006 9.92 ALB EGFR ERBB2 HRAS IL2 IL6
9 no phenotypic analysis MP:0003012 9.86 CD274 CD4 EGFR HRAS IL2 KIT
10 normal MP:0002873 9.81 ALB CCR6 CD4 CD8A CTLA4 EGFR
11 respiratory system MP:0005388 9.61 CTLA4 EGFR ERBB2 HRAS IL2 IL6
12 skeleton MP:0005390 9.32 CD274 CTLA4 EGFR ERBB2 GPT HRAS
Sources

Drugs & Therapeutics for Exanthem

About this section

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nevirapine Approved Phase 4 129618-40-2 4463
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Tocopherol Approved, Investigational Phase 4 1406-66-2
6
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
7
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
8
Menthol Approved Phase 4 2216-51-5 16666
9
Allantoin Approved Phase 4 97-59-6 204
10
Pancrelipase Approved, Investigational Phase 4 53608-75-6
11
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
12 Tocotrienol Investigational Phase 4 6829-55-6
13 Vitamin K 1 Phase 4
14 Anti-Infective Agents Phase 4
15 Reverse Transcriptase Inhibitors Phase 4
16 Antiviral Agents Phase 4
17 Anti-Retroviral Agents Phase 4
18 Antibiotics, Antitubercular Phase 4
19 Anti-Bacterial Agents Phase 4
20 Antiparasitic Agents Phase 4
21 Antiprotozoal Agents Phase 4
22 Antimalarials Phase 4
23 Emollients Phase 4
24 Liver Extracts Phase 4
25 Aloe Phase 4
26 Tocotrienols Phase 4
27 Tocopherols Phase 4
28 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
29 Hypoglycemic Agents Phase 4
30 Sodium-Glucose Transporter 2 Inhibitors Phase 4
31 Anti-HIV Agents Phase 4
32 pancreatin Phase 4
33
Gefitinib Approved, Investigational Phase 2, Phase 3 184475-35-2 123631
34
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 12560
35
Fusidic Acid Approved, Investigational Phase 3 6990-06-3 3000226
36
Afamelanotide Approved, Investigational Phase 3 75921-69-6
37
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
38
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
39 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
40
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
41
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
42
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
43
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
44
Desloratadine Approved, Investigational Phase 3 100643-71-8 124087
45 Coconut Approved Phase 3
46
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
47
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
48
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
49
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
50
Maleic acid Experimental Phase 3 110-16-7 444266

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
2 A Parallel, Evaluator-Blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Two Marketed Topical Skin Protectants Containing Zinc Oxide in Children With Diaper Rash Completed NCT00219466 Phase 4
3 Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
4 A Multi-center, Double-blinded Randomized Trial for Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
5 Randomized Controlled Trial Comparing the Efficacy and Safety of Calmoseptine Ointment and Desitin Maximum Strength 40% Zinc Oxide Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Completed NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
6 The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment Completed NCT01318356 Phase 4 Doxycycline;Placebo
7 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Completed NCT04193566 Phase 4 Forxiga
8 A Multicenter, Randomized, Open-label, Controlled Study of Nevirapine (VIRAMUNE®) and a Short Course of Prednisone to Determine the Safety and Effectiveness of This Strategy in Preventing Nevirapine (VIRAMUNE®) Associated Rash. Completed NCT02184299 Phase 4 Nevirapine;Prednisone
9 The Healthy Baby Bottoms Study: A Trial of Theraworx Foam Formulation for the Prevention and Treatment of Diaper Dermatitis Suspended NCT04101890 Phase 4 Diaper care with Theraworx
10 Randomized, Double Blind, Placebo-controlled Trial of Creon in Patients With Low Faecal Pancreatic Elastase Terminated NCT01865695 Phase 4 Creon
11 Pilot Study of Acitretin for Treatment of Erlotinib-induced Skin Rash Withdrawn NCT01299220 Phase 4 Acitretin
12 A Clinical Observation to Assess the Safety and Consumers' Satisfaction of Moussik vs Desitin Creamy Ointment in Prophylaxis of Diaper Rash. A Single Blind, Multicenter, Randomized, Cross-over Study Withdrawn NCT01167465 Phase 4
13 Neotililty Trial: Effect of Coenzyme Q10 on Semen Parameters in Men With Idiopathic Infertility Withdrawn NCT03104998 Phase 4 Coenzyme Q10
14 Gefitinib Alone or With Concomitant Whole Brain Radiotherapy for Patients Harboring an EGFR Mutation With Multiple Brain Metastases From Non-Small-cell Lung Cancer: a Phase II/III Randomized Controlled Trial Unknown status NCT02338011 Phase 2, Phase 3 Gefitinib
15 A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
16 Glucocorticoids Associated With Antihistamines Versus Antihistamines Randomized Double Blinded for the Management of Acute Urticaria in Emergency Completed NCT02565680 Phase 2, Phase 3 placebo;prednisone
17 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Topical Sunscreen to Prevent Erlotinib- or Cetuximab-Induced Skin Rash [or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash] Completed NCT00362986 Phase 3 sunscreen
18 A Randomized Controlled Clinical Study Comparing the Efficacy and Safety of Calmoseptine vs Destin Maximum Strength Diaper Rash Paste in Treatment of Incontinence Associated Dermatitis in Older Children and Adults Completed NCT02080247 Phase 3 Skin care regimen with Calmoseptine ointment;Skin care regimen with Destin ointment
19 A Randomized, Open Label Study to Compare the Use of the Dermatological Creams Verutex, Eritex and Fisiogel in the Management of Skin Rash Associated With Tarceva Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer. Completed NCT00718315 Phase 3 erlotinib [Tarceva];fusidic acid [Verutex];erythromycin [Eritex];Fisiogel
20 A Randomized, Double-blind, Prospective Trial of Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in Non-small Cell Lung Cancer Completed NCT01528488 Phase 2, Phase 3
21 Phase III Randomized Double-Blind Trial of Bepanthen® Cream Versus Cetomacrogol Cream in the Prevention of Papulopustular Eruption in Patients Receiving Epidermal Growth Factor Receptor Inhibitors (EGFRI): BeCet Completed NCT01136005 Phase 3
22 A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE) Completed NCT04704713 Phase 3 Afamelanotide;Placebo
23 A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Acute Cutaneous Rash Terminated NCT01529242 Phase 3 Desloratadine + Prednisolone;Dexchlorpheniramine + Betamethasone
24 Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial Terminated NCT01595893 Phase 3 Oral Vitamin D 3;Miglyol 812 N
25 Protocol Establishment for the Prevention of Lamotrigine-induced Skin Rash in Epilepsy Patients: A Pilot Study Unknown status NCT03220256 Phase 2 Lamotrigine
26 A Phase II Randomized, Double Blind, Placebo Study to Evaluate the Efficacy of Vitamin K1 Cream Treatment Compared to Placebo for the Prevention of Papulo-pustular Rash in Metastatic Colorectal Patients Receiving First Line EGFRI Treatment. Unknown status NCT01763307 Phase 2 RECONVAL CREAM;PLACEBO
27 Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances Unknown status NCT01729481 Phase 2 Gemcitabine;Erlotinib;Oxaliplatin;Folinic Acid;Irinotecan;5-FU
28 An Open-label, Multicenter, Efficacy and Safety Study of 4-month Canakinumab Treatment With 6-month Follow-up in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS). Completed NCT01242813 Phase 2 ACZ885
29 A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy. Completed NCT00886795 Phase 1, Phase 2 abatacept (Orencia ®)
30 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group With a Crossover Confirmation Period Study of RWJ-333369 for the Treatment of Postherpetic Neuralgia. Completed NCT00492323 Phase 2 placebo;carisbamate
31 A Phase II Randomized Study of OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer (NSCLC) Completed NCT00230126 Phase 2 erlotinib
32 A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer Completed NCT00473083 Phase 2 Minocycline;Clindamycin 2% in hydrocortisone 1% lotion;Erlotinib;Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
33 Double Blind Placebo Controlled Trial, for Evaluating Preventive Therapy With Either Oint Threolone Versus Synthomycine Versus Aqua Cream, for EGFR'I Induced Acneiform Rash Completed NCT01256437 Phase 2 Threolone ointment;ointment Synthomycine;Aqua cream
34 Phase II, Open-label, Single Blind, Randomised Clinical Trial With Tetracycline as a Prophylaxis for Rash and Dermatological Recommendations Versus Dermatological Recommendations in Patients With NSCLC Receiving Treatment With BIBW 2992 Completed NCT01880515 Phase 2 Tetracycline
35 Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor Completed NCT03440515 Phase 2 Prednisone
36 The Use of Campath-1H, Tacrolimus, and Sirolimus Followed by Sirolimus Withdrawal in Renal Transplant Patients Completed NCT00078559 Phase 1, Phase 2 Alemtuzumab;Sirolimus;Tacrolimus;Methylprednisolone (or equivalent);Acetaminophen;Diphenhydramine;Trimethoprim (TMP)/Sulfa (Bactrim, Septra);Valgancyclovir;Acyclovir;Pentamidine;Clotrimazole;Nystatin
37 A Safety, Tolerability and Efficacy Study of Doxycycline Topical Foam Administered Topically for Prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects With Cancer Receiving Cetuximab or Panitumumab Completed NCT02239731 Phase 2 FDX104 (4% Doxycycline)
38 A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC) Completed NCT00589667 Phase 2 Pemetrexed plus Gemcitabine
39 A Phase II, Open-label, Intra-patient Dose-escalation Study of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed Prior Chemotherapy Completed NCT00072631 Phase 2 Tarceva (Trademark) (erlotinib HCl, OSI-774)
40 A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver Completed NCT00803647 Phase 2 5-FU;oxaliplatin;leucovorin
41 A Multi-Center Study Investigating the Correlation Between TARCEVA ®-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy Completed NCT01174563 Phase 2 erlotinib [Tarceva]
42 A Two-Part, Phase II Randomized Trial to Explore Topical Spironolactone to Prevent/Attenuate Rash From Epidermal Growth Factor Receptor Inhibitors (Panitumumab and Cetuximab) in Advanced Cancer Patients Completed NCT01867294 Phase 2 Doxycycline;Spironolactone;Sunscreen;Therapeutic Hydrocortisone
43 An Open Label Study of Tarceva in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas : Relationship Between Skin Rash and Survival Completed NCT00461708 Phase 2 Erlotinib;Gemcitabine
44 A Randomized, Open-label, Dose-escalation to Rash Study to Assess the Effect of Tarceva in Combination With Gemcitabine on Overall Survival in Patients With Metastatic Pancreatic Cancer. Completed NCT00652366 Phase 2 Erlotinib, escalating dose;Erlotinib, standard dose;Gemcitabine
45 A Phase II Trial Assessing Metronidazol Actavis 1% Topical Cream in the Prevention and Treatment of Erlotinib Associated Rash Completed NCT00642473 Phase 2 Erlotinib;Metronidazole Actavis
46 A Randomized, Open Label Study to Evaluate the Effect of Doxycycline on Tarceva-induced Skin Rash in Patients With Non-small Cell Lung Cancer After Failure of First Line Chemotherapy Completed NCT00531934 Phase 2 Doxycline;erlotinib [Tarceva]
47 A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab Completed NCT00332163 Phase 2 Irinotecan;FOLFIRI;Pre-emptive Skin Treatment;Reactive Skin Treatment
48 Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label Recruiting NCT03363763 Phase 2 Sirolimus 0.2%;Sirolimus 0.4%;Placebo ointment
49 A Phase II Study of Thiotepa Added to Fludarabine and Melphalan as the Preparative Regime for Alternative Donor Transplantation Recruiting NCT03342196 Phase 2 Melphalan;Thiotepa;Fludarabine;Keratinocyte Growth Factor (KGF)
50 A Randomized, Double-blind, Placebo-controlled Trial of AC-701 for Treatment of Skin Rash in Subjects With EGFR Inhibitor Therapy Recruiting NCT04239846 Phase 2 AC-701 Topical Gel 0.3%

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Sources

Genetic Tests for Exanthem

About this section
Sources

Anatomical Context for Exanthem

About this section

MalaCards organs/tissues related to Exanthem:

40
Skin, Breast, Myeloid, Brain, Bone Marrow, Heart, Kidney
Sources

Publications for Exanthem

About this section

Articles related to Exanthem:

(show top 50) (show all 27694)
# Title Authors PMID Year
1
Efficacy of different plant extracts in the prevention of radiation dermatitis in radiotherapy patients with nasopharyngeal carcinoma: A protocol for a Bayesian network meta-analysis. 42
33371074 2020
2
HLA-A∗24:02 associated with lamotrigine-induced cutaneous adverse drug reactions: A systematic review and meta-analysis. 42
33350798 2020
3
COMMON ALLERGIES AND ALLERGENS IN ORAL AND PERIORAL DISEASES. 42
33456120 2020
4
Qingxue jiedu formulation ameliorated DNFB-induced atopic dermatitis by inhibiting STAT3/MAPK/NF-κB signaling pathways. 61
33388430 2021
5
Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer. 61
33140306 2021
6
Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials. 61
33119182 2021
7
Persistent Arcuate and Annular Rash: Answer. 61
33595231 2021
8
Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sézary syndrome. 61
33604439 2021
9
Persistent Arcuate Annular Rash: Challenge. 61
33595235 2021
10
Carbamazepine versus levetiracetam in epilepsy due to neurocysticercosis. 61
33006755 2021
11
"Fake news" in dermatology. Results from an observational, cross-sectional study. 61
33095467 2021
12
Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. 61
33604462 2021
13
Antinuclear Antibody Testing for the Diagnosis of Systemic Lupus Erythematosus. 61
33589110 2021
14
Atypical systemic and dermatologic loxoscelism in a non-endemic region of the USA. 61
32757843 2021
15
The perception gap of chemotherapy-induced adverse events between doctors and cancer patients: an observational study in China. 61
32728801 2021
16
Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children. 61
33028102 2021
17
Analysis of the first 5 years of an interdisciplinary Rheumatology-Dermatology clinic. 61
32687656 2021
18
Amniotic membrane transplantation in a 2-month-old infant with toxic epidermal necrolysis. 61
33521381 2021
19
Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. 61
33309774 2021
20
Abnormal Nailfold Capillaroscopy in a Patient With Multisystem Inflammatory Syndrome in Children. 61
33565816 2021
21
A Japanese-American female with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. 61
32676922 2021
22
Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. 61
32889976 2021
23
Calciphylaxis: The potential diagnostic role of radiologists. 61
33363673 2021
24
Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. 61
33025080 2021
25
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. 61
33159216 2021
26
Comparison of Safety, Efficacy, Patient Compliance and Cost-Effectiveness of Transdermal, Oral and Intramuscular Diclofenac for Pain Control Following Oral Surgical Procedures. 61
33584044 2021
27
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. 61
33387727 2021
28
Erlotinib and bevacizumab in elderly patients ≥75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations. 61
32803701 2021
29
Distinguishing Blau Syndrome from Systemic Sarcoidosis. 61
33560445 2021
30
Inherited genetic late-onset erythropoietic protoporphyria: a systematic review of the literature. 61
33556208 2021
31
Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report. 61
33598239 2021
32
Tofacitinib-induced subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis. 61
33492185 2021
33
[Skin Manifestations in Dermatomyositis and Antisynthetase Syndrome]. 61
33561828 2021
34
Pathways of Neutrophil Granulocyte Activation in Hereditary Angioedema with C1 Inhibitor Deficiency. 61
33606193 2021
35
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-Term Extension of RESILIENT. 61
33597289 2021
36
Pruritic genital rash. 61
33600633 2021
37
A widespread rash with optic neuritis. 61
33554354 2021
38
Family rash. 61
33243611 2021
39
Mycoplasma pneumoniae-Induced Rash and Mucositis in a Young Adult. 61
33091392 2021
40
Erythema nodosum-like rash in a COVID-19 patient: A case report. 61
32828595 2021
41
A case of COVID-19 with papulovesicular rash that progressed to retiform purpura, accompanied by cherry angiomas. 61
33566880 2021
42
[Generalized rash with osimertinib therapy for non-small cell bronchial carcinoma]. 61
32852597 2021
43
Pruritic genital rash. 61
33600637 2021
44
A narrative review of reward sensitivity, rash impulsivity, and food addiction in adolescents. 61
33545225 2021
45
SDRIFE-like rash associated with COVID-19, clinicopathological correlation. 61
32815151 2021
46
Recalcitrant Rash in a 7-month-old Infant. 61
33526580 2021
47
Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Probably Related to Cefpodoxime: A Case Report. 61
31382812 2021
48
Widespread rash as initial presentation of acute hepatitis E in a woman with well-controlled HIV. 61
33530880 2021
49
Black spots and skin rash with fever in hunting preserve worker. 61
32536598 2021
50
Commentary on "An Isolated Peculiar Gianotti-Crosti Rash in the Course of a COVID-19 Episode". 61
33554263 2021
Sources

Variations for Exanthem

About this section

ClinVar genetic disease variations for Exanthem:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SYK NM_003177.7(SYK):c.1649C>T (p.Ser550Phe) SNV Pathogenic 989386 9:93650098-93650098 9:90887816-90887816
2 SYK NM_003177.7(SYK):c.1649C>A (p.Ser550Tyr) SNV Pathogenic 989389 9:93650098-93650098 9:90887816-90887816
3 SYK NM_003177.7(SYK):c.1350G>A (p.Met450Ile) SNV Likely pathogenic 989237 9:93640021-93640021 9:90877739-90877739
4 SYK NM_003177.7(SYK):c.1024C>A (p.Pro342Thr) SNV Likely pathogenic 989387 9:93636974-93636974 9:90874692-90874692
5 SYK NM_003177.7(SYK):c.1057G>A (p.Ala353Thr) SNV Uncertain significance 989236 9:93637007-93637007 9:90874725-90874725
Sources

Expression for Exanthem

About this section
Search GEO for disease gene expression data for Exanthem.
Sources

Pathways for Exanthem

About this section

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.86 TNF SYK KIT IL6 IL2 IFNA1
2
PEDF Induced Signaling 63
Show member pathways
 13.71 TNF KIT IL6 IL2 IFNA1 HRAS
3
TGF-Beta Pathway 63
Show member pathways
 13.58 TNF KIT IL6 IL2 IFNA1 HRAS
4
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.43 SYK KIT ICOSLG HRAS ERBB2 EGFR
5
Akt Signaling 63
Show member pathways
 13.38 TNF SYK KIT IL6 IL2 HRAS
6
CREB Pathway 63
Show member pathways
 13.36 SYK KIT IL6 IL2 HRAS ERBB2
7
Cytokine Signaling in Immune system 65
Show member pathways
 13.32 TNF SYK KIT IL6 IL2 IFNA1
8
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.3 TNF KIT IL6 IL2 HRAS ERBB2
9
PAK Pathway 63
Show member pathways
 13.3 TNF KIT IL6 IL2 HRAS ERBB2
10
Phospholipase-C Pathway 63
Show member pathways
 13.1 SYK KIT IL6 IL2 HRAS EGFR
11
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.09 TNF SYK IL6 IL2 IFNA1 HRAS
12
p70S6K Signaling 63
Show member pathways
 13.08 SYK KIT IL6 IL2 HRAS EGFR
13
Human cytomegalovirus infection 36
Show member pathways
 12.97 TNF SYK IL6 IFNA1 HRAS EGFR
14
PI3K-Akt signaling pathway 36
Show member pathways
 12.92 TNF SYK KIT IL6 IL2 IFNA1
15
Pathways in cancer 36
12.85 KIT IL6 IL2 IFNA1 HRAS ERBB2
16
MAPK signaling pathway 36 1
12.8 TNF KIT HRAS ERBB2 EGFR
17
Allograft rejection 36 1
Show member pathways
 12.8 TNF IL6 IL2 IFNA1 ICOSLG CTLA4
18
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.76 SYK KIT HRAS ERBB2 EGFR
19
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.75 TNF IL6 IFNA1 HRAS EGFR
20
Immune response NFAT in immune response 23
Show member pathways
 12.67 TNF SYK IL2 ICOSLG HRAS CD4
21
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.56 TNF SYK IL2 IFNA1 HRAS
22
Immune response IL-23 signaling pathway 23
Show member pathways
 12.55 TNF IL6 IL2 HRAS ERBB2 EGFR
23
JAK-STAT signaling pathway 36
Show member pathways
 12.45 IL6 IL2 IFNA1 HRAS EGFR
24
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.44 KIT IL6 IL2 HRAS ERBB2 EGFR
25
NF-kappaB Signaling 4
12.44 TNF SYK KIT IL2 IFNA1 CTLA4
26
ICos-ICosL Pathway in T-Helper Cell 63
Show member pathways
 12.43 SYK IL2 ICOSLG CTLA4 CD4
27
Human T-cell leukemia virus 1 infection 36
12.38 TNF IL6 IL2 HRAS CD4
28
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.37 TNF IL6 IL2 CCR6
29
Folate Metabolism 1
Show member pathways
 12.37 TNF IL6 IL2 CRP ALB
30
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 12.35 IL6 HRAS ERBB2 EGFR
31
Proteoglycans in cancer 36
12.33 TNF HRAS ERBB2 EGFR
32
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.29 TNF KIT IL6 IL2 IFNA1 EGFR
33
Tuberculosis 36
12.26 TNF SYK IL6 IFNA1
34
CD28 co-stimulation 65
Show member pathways
 12.24 ICOSLG CTLA4 CD4 CD274
35
C-type lectin receptor signaling pathway 36
Show member pathways
 12.24 TNF SYK IL6 IL2 HRAS
36
Tyrosine Kinases / Adaptors 4
12.16 SYK KIT ERBB2 EGFR
37
Cell adhesion molecules 36
12.16 ICOSLG CTLA4 CD8A CD4 CD274
38
Yersinia infection 36
12.09 TNF IL6 IL2 CD8A CD4
39
Spinal Cord Injury 1
12.06 TNF IL6 IL2 EGFR
40
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.95 TNF KIT IL6 IL2 CD8A CD4
41
Hematopoietic cell lineage 36
11.92 TNF KIT IL6 CD8A CD4
42
T cell receptor signaling pathway 36
Show member pathways
 11.82 TNF IL6 IL2 HRAS EGFR CTLA4
43
Th1 Differentiation Pathway 64
Show member pathways
 11.81 TNF IL6 IL2 CD4
44
G-protein signaling_RhoA regulation pathway 23
11.78 IL6 IL2 HRAS ERBB2 EGFR
45
Bladder cancer 36 1
11.77 HRAS ERBB2 EGFR
46
CTLA4 Signaling 63
11.77 SYK CTLA4 CD8A CD4
47
Central carbon metabolism in cancer 36
11.76 KIT HRAS ERBB2 EGFR
48
LPA receptor mediated events 1
11.71 IL6 HRAS EGFR
49
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.69 TNF IL6 IL2
50
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.67 TNF IL2 CD8A
Sources

GO Terms for Exanthem

About this section

Cellular components related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 TNF KIT ERBB2 EGFR CTLA4 CD8A
2 cell surface GO:0009986 9.63 TNF KIT EGFR CD4 CD274 CCR6
3 extracellular space GO:0005615 9.61 TNF KIT IL6 IL2 IFNA1 GPT
4 external side of plasma membrane GO:0009897 9.23 TNF KIT ICOSLG CTLA4 CD8A CD4

Biological processes related to Exanthem according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.27 KIT IL6 IFNA1 ICOSLG HRAS ERBB2
2 immune system process GO:0002376 10.12 SYK IL2 ICOSLG CTLA4 CD8A CD4
3 positive regulation of cell proliferation GO:0008284 10.08 KIT IL6 IL2 HRAS ERBB2 EGFR
4 positive regulation of gene expression GO:0010628 10.06 TNF KIT IL6 HRAS ERBB2 CRP
5 cytokine-mediated signaling pathway GO:0019221 9.99 TNF KIT IL6 IL2 IFNA1 CD4
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 TNF HRAS EGFR CD4
7 MAPK cascade GO:0000165 9.97 TNF KIT IL2 HRAS ERBB2 EGFR
8 positive regulation of protein kinase B signaling GO:0051897 9.96 TNF KIT ERBB2 EGFR
9 T cell receptor signaling pathway GO:0050852 9.95 ICOSLG HRAS CTLA4 CD4
10 protein autophosphorylation GO:0046777 9.94 SYK KIT ERBB2 EGFR
11 peptidyl-tyrosine phosphorylation GO:0018108 9.91 SYK KIT ERBB2 EGFR
12 positive regulation of protein phosphorylation GO:0001934 9.88 TNF IL2 HRAS ERBB2 EGFR CD4
13 cell surface receptor signaling pathway GO:0007166 9.87 SYK HRAS ERBB2 EGFR CD8A CD4
14 immune response GO:0006955 9.86 TNF IL6 IL2 CTLA4 CD8A CD4
15 positive regulation of interferon-gamma production GO:0032729 9.85 TNF IL2 HRAS
16 positive regulation of epithelial cell proliferation GO:0050679 9.85 HRAS ERBB2 EGFR
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 TNF KIT IL6 IL2
18 positive regulation of smooth muscle cell proliferation GO:0048661 9.84 TNF IL6 EGFR
19 positive regulation of T cell proliferation GO:0042102 9.84 IL6 IL2 CD4 CD274
20 positive regulation of interleukin-8 production GO:0032757 9.83 TNF SYK IL6
21 humoral immune response GO:0006959 9.83 TNF IL6 IFNA1 CCR6
22 positive regulation of MAPK cascade GO:0043410 9.83 KIT IL6 HRAS ERBB2 CD4
23 T cell costimulation GO:0031295 9.82 ICOSLG CTLA4 CD274
24 T cell activation GO:0042110 9.81 ICOSLG CD8A CD4
25 T cell differentiation GO:0030217 9.8 KIT IL2 CD4
26 positive regulation of interleukin-10 production GO:0032733 9.79 SYK IL6 CD274
27 positive regulation of JAK-STAT cascade GO:0046427 9.77 TNF KIT IL6
28 regulation of ERK1 and ERK2 cascade GO:0070372 9.77 SYK ERBB2 EGFR
29 positive regulation of kinase activity GO:0033674 9.77 KIT IL2 ERBB2 EGFR CD4
30 adaptive immune response GO:0002250 9.76 SYK IL2 IFNA1 ICOSLG CTLA4 CD8A
31 positive regulation of superoxide anion generation GO:0032930 9.73 SYK EGFR CRP
32 vascular endothelial growth factor production GO:0010573 9.66 TNF IL6
33 negative regulation of ERBB signaling pathway GO:1901185 9.65 ERBB2 EGFR
34 negative regulation of lipid storage GO:0010888 9.65 TNF IL6 CRP
35 leukocyte activation involved in immune response GO:0002366 9.63 SYK IL2
36 enzyme linked receptor protein signaling pathway GO:0007167 9.63 SYK ERBB2 CD4
37 positive regulation of MAP kinase activity GO:0043406 9.35 TNF KIT HRAS ERBB2 EGFR
38 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.1 SYK KIT ERBB2 EGFR CD8A CD4

Molecular functions related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 KIT ERBB2 EGFR
2 protein tyrosine kinase activity GO:0004713 8.92 SYK KIT ERBB2 EGFR
Sources

Sources for Exanthem

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....